Document Detail


Initial clinical study with pyrazofurin.
MedLine Citation:
PMID:  872139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-five patients with inoperable carcinoma and lymphoma were given pyrazofurin (pf) by iv bolus at a dose level ranging from 100 to 300 mg/m2 of estimated body surface area. In addition, five patients with acute leukemia were given PF by infusion at doses ranging from 250 mg/m2/24 hours to 1500 mg/m2/144 hours. PF was well tolerated by most patients at doses of 100 mg/m2 given as an iv bolus weekly or 250 mg/m2 given every 2-3 weeks. However, an infusion of 750 mg/m2 given over a period of 72-120 hours to leukemic patients resulted in severe but reversible toxicity; 1500 mg/m2 of PF given over a 144-hour period to one patient resulted in the development of severe mucocutaneous toxicity and leukopenia. The patient died of hemorrhagic pneumonitis. The major toxic effects observed were mucosal (oral pain, cheilosis, redness, and oral and lip ulcers), cutaneous (erythema, erosion, and bullae), and hematologic (anemia, leukopenia, and thrombocytopenia). The mucosal manifestations appear to be the dose-limiting toxic factors in most patients. Toxic reactions were more pronounced in patients who had previously received radiotherapy; dose-limiting hematologic toxic reactions occurred in four. After treatment with PF, one of the four patients with breast carcinoma had a partial response (greater than 50% regression) lasting 5 weeks. Another patient with breast carcinoma improved for about 1 month.
Authors:
T Ohnuma; J F Holland
Related Documents :
22248739 - Long-term treatment outcome of minor salivary gland carcinoma of the hard palate.
6275989 - Phase i-ii study of isotopic immunoglobulin therapy for primary liver cancer.
21900539 - T1-t2 squamous cell carcinoma of the uvula: a little big enemy.
21594329 - Treatment of hepatocellular carcinoma associated with extrahepatic primary cancer.
2272769 - A phase ii study of mitoxantrone in advanced gastric cancer.
10857889 - 21-day oral etoposide for metastatic breast cancer: a phase ii study and review of the ...
10432429 - Brachytherapy in the treatment of colorectal malignancies.
19846349 - High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal c...
16203289 - Cytologic grade independently predicts survival of patients with pancreatic adenocarcin...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  61     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:    1977 May-Jun
Date Detail:
Created Date:  1977-08-25     Completed Date:  1977-08-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  389-94     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antibiotics, Antineoplastic / administration & dosage,  adverse effects,  therapeutic use*
Breast Neoplasms / drug therapy
Child
Drug Administration Schedule
Drug Evaluation
Erythema / chemically induced
Female
Humans
Infusions, Parenteral
Injections, Intravenous
Leukemia / drug therapy
Male
Middle Aged
Mucous Membrane / drug effects
Neoplasms / drug therapy*
Ribonucleosides / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Ribonucleosides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characte...
Next Document:  Drug activation by gamma irradiation: a new direction for molecular design. Part I: In vitro and in ...